| Description | The antibody CS44 (VH1-58 mAb) is a neutralizing antibody against SARS-CoV-2 Spike S1, derived from human. It targets the RBD (receptor binding domain) of SARS-CoV-2 Spike S1. The antibody has the neutralizing ability against authentic Beta, Delta and wildtype virus. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Cross Reactivity | Wildtype, Alpha, Beta, Gamma, Delta |
| Epitope | The dominant interaction of the antibody is with the RBD ridge region (residues 471-491). |
| IC50 | <200 ng/mL |
| Affinity | 10-100 nM |
| Isotype | Human IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; BLI; Neut |
| Application Notes | For ELISA, mAbs was tested at 100 ng/ml for binding to RBD Beta, wildtype RBD as well as RBD variants. For Surface plasmon resonance (SPR), purified mAbs were reversibly immobilized via the anti-human IgG capture surface. For Bio-layer interferometry (BLI), IgG was diluted with kinetic buffer (1x PBS, pH 7.4, 0.01% BSA and 0.002% Tween 20). In Neutralization assay, the mAbs was diluted 1:10 with sample dilution buffer, mixed 1:1 with wildtype HRP-RBD or Beta HRP-RBD solution and incubated at 37°C for 30 minutes. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
